A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Bassali, J. [1 ]
Gould, I [2 ]
Mladsi, D. D. [2 ]
Kaye, J. A. [3 ]
Shah, J. [1 ]
Mehta, J. [4 ]
机构：
[1] Karyopharm Therapeut, Newton, MA USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] RTI Hlth Solut, Waltham, MA USA
[4] Karyopharm Therapeut, Lexington, MA USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN58
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [21] Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)
    Baz, Rachid
    Zonder, Jeffrey A.
    Shain, Kenneth H.
    Alsina, Melissa
    Brayer, Jason B.
    Melody, Mark
    Turner, Joel G.
    Dawson, Jana L.
    Kim, Jongphil
    Sullivan, Daniel M.
    BLOOD, 2017, 130
  • [22] Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Nam, Jennifer
    Severson, Erica
    Stephens, Leonor A.
    McDonnell, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd
    Karrison, Theodore
    Zonder, Jeffrey
    BLOOD, 2016, 128 (22)
  • [23] Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    Palumbo, Antonio
    Dimopoulos, Meletios
    San Miguel, Jesus
    Harousseau, Jean-Luc
    Attal, Michel
    Hussein, Mohamad
    Knop, Stefan
    Ludwig, Heinz
    von Lilienfeld-Toal, Marie
    Sonneveld, Pieter
    BLOOD REVIEWS, 2009, 23 (02) : 87 - 93
  • [24] BUDGET IMPACT OF ELRANATAMAB-BCMM IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE UNITED STATES
    Shah, B.
    Sandin, R.
    Liu, Y.
    Hu, Y.
    Schepart, A.
    Hughes, D.
    Hart, J.
    Hlavacek, P.
    VALUE IN HEALTH, 2024, 27 (06) : S136 - S136
  • [25] Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM)
    White, Darrell
    Schiller, Gary J.
    Madan, Sumit
    Lentzsch, Suzanne
    Chubar, Evgeni
    Lavi, Noa
    Van Domelen, Dane R.
    Bentur, Ohad S.
    Baljevic, Muhamed
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Gasparetto, Cristina
    Schiller, Gary J.
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Tuchman, Sascha A.
    Bahlis, Nizar
    White, Darrell J.
    Chen, Christine I.
    Sutherland, Heather J.
    Baljevic, Muhamed
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Lipe, Brea C.
    BLOOD, 2019, 134
  • [27] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
    Tognazzi, L.
    Rivolti, E.
    Quaresima, M.
    Labbozzetta, S.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2017, 102 : 137 - 137
  • [28] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Ghanem, Buthainah
    Shi, Lu
    CLINICAL DRUG INVESTIGATION, 2022, 42 (12) : 1085 - 1092
  • [29] Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US
    Buthainah Ghanem
    Lu Shi
    Clinical Drug Investigation, 2022, 42 : 1085 - 1092
  • [30] Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM)
    Zonder, Jeffrey
    Lee, Hans
    Richter, Joshua
    Bumma, Naresh
    Zhou, Zheng-Yi
    Garcia-Horton, Viviana
    Fillbrunn, Mirko
    Wang, Hongjue
    Mattera, Matthew
    Ma, Wenxin
    Ma, Qiufei
    Inocencio, Timothy
    Xu, Yingxin
    Bergrath, Evelien
    Harnett, James
    Roccia, Tito
    Kroog, Glenn S.
    Lorenc, Karen Rodriguez
    Houvras, Yariv
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S267 - S267
12345